Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Theratechnologies Inc.

http://www.theratech.com

Latest From Theratechnologies Inc.

Japan Finally Approves Mifepristone To Public Support

Japan has approved abortion drug mifepristone but will limit its use to clinics with authorized physicians, with strict nationwide monitoring of sales. The majority of more than 10,000 public comments around the approval were in support of the new option for women. 

Japan Approvals

Gilead Waives Acquisition Option As Pionyr Explores Other Strategies

Gilead has waived its option to acquire Pionyr, allowing the US biotech to explore other partnerships and financing opportunities as it advances a promising pipeline of macrophage-targeting antibodies.

Deals Cancer

Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances

Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.

Scrip Asks Research & Development

Faron Set To Fly As Bexmarilimab Shows Promise

Data have shown that the Finnish firm's bexmarilimab has the potential to be the first macrophage immune checkpoint therapy and big pharma are getting interested in a licensing deal.

Clinical Trials ImmunoOncology
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Katana Biopharma, Inc.
UsernamePublicRestriction

Register